Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer

• Status: Recruiting
• Trial end date: 2023-11-01

Summary

The purpose of this study is to test the safety of adding a new drug, durvalumab (also called MEDI4736), to chemoradiation with either FOLFOX/Capeox or carboplatin and paclitaxel, following initial chemotherapy with FOLFOX. The investigators want to find out what effects, good and/or bad, this combination has on the patient and cancer.

• Phase: Phase 1/Phase 2

Details

• Lead Sponsor: Memorial Sloan Kettering Cancer Center
• Collaborator: AstraZeneca
• Treatments: Albumin-Bound Paclitaxel; Antibodies; Antibodies, Monoclonal; Carboplatin; Durvalumab; Paclitaxel; Tremelimumab